Abstract
Abstract
Introduction
The prognostic role of plasma neurofilament light chain (NfL), phospho-tau, beta-amyloid, and GFAP is still debated in Parkinson’s disease (PD).
Methods
Plasma p-tau181, p-tau231, Aβ1-40, Aβ1-42, GFAP, and NfL were measured by SIMOA in 136 PD with 2.9 + 1.7 years of follow-up and 76 controls. Differences in plasma levels between controls and PD and their correlation with clinical severity and progression rates were evaluated using linear regression analyses.
Results
Patients exhibited similar distribution of plasma biomarkers but higher P-tau181, P-tau231 and lower Aβ1-42 compared with controls. NfL and GFAP correlated with baseline motor and non-motor severity measures. At follow-up, NfL emerged as the best predictor of progression with marginal effect of GFAP and p-tau181 adjusting for age, sex, disease duration, and baseline motor severity.
Conclusion
The present findings confirmed plasma NfL as best predictor of progression in PD, with a marginal role of p-tau181 and GFAP.
Funder
Ministero dell’Istruzione, dell’Università e della Ricerca
RePlast
Airalzh Foundation
Health and Wealth research grants 2016 of the University of Brescia
H2020 European Research Council
Ministero della Salute
PNRR-Health
Swedish Research Council
Swedish Alzheimer Foundation
Hjärnfonden
ALF-agreement
European Union Joint Program for Neurodegenerative Disorders
Office of Dietary Supplements
HORIZON EUROPE Reforming and enhancing the European Research and Innovation system
Swedish State Support for Clinical Research
Alzheimer Drug Discovery Foundation
AD Strategic Fund and the Alzheimer's Association
Bluefield Project
Familjen Erling-Perssons Stiftelse
Stiftelsen för Gamla Tjänarinnor
H2020 Marie Skłodowska-Curie Actions
EU Joint Programme – Neurodegenerative Disease Research
UCLH Biomedical Research Centre
Università degli Studi di Brescia
Publisher
Springer Science and Business Media LLC